Overexpression of HSPA2 is correlated with poor therapeutic outcomes in human breast cancer, cervical cancer and bladder urothelial cancer; furthermore, it is now a valuable prognostic marker for breast cancer patients[7]. The gene discussed is HSPA2; the disease is bladder transitional cell carcinoma.